Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Compass Therapeutics (CMPX) has appointed Barry Shin as Chief Financial Officer effective December 9, 2024. Shin brings over 20 years of experience in biopharmaceutical leadership, including finance, operations, investment banking, and corporate advisory roles. Most recently, he served as EVP, COO & CFO at Trevena, Inc.
The appointment comes at a important time for Compass, with several key catalysts expected in 2025, including topline data readout for CTX-009 in the first quarter. CEO Thomas Schuetz highlighted Shin's expertise in financial planning, capital markets, and M&A as valuable assets for advancing CTX-009 and the company's portfolio of clinical and pre-clinical assets.
Compass Therapeutics (CMPX) ha nominato Barry Shin come Chief Financial Officer a partire dal 9 dicembre 2024. Shin porta con sé oltre 20 anni di esperienza nella leadership biopharmaceutica, inclusi ruoli in finanza, operazioni, investment banking e consulenza aziendale. Recentemente, ha ricoperto il ruolo di EVP, COO e CFO presso Trevena, Inc.
La nomina arriva in un momento significativo per Compass, con diversi catalizzatori chiave previsti nel 2025, tra cui la lettura dei dati principali per CTX-009 nel primo trimestre. Il CEO Thomas Schuetz ha sottolineato l’esperienza di Shin nella pianificazione finanziaria, nei mercati dei capitali e nelle fusioni e acquisizioni come beni preziosi per far progredire CTX-009 e il portafoglio di asset clinici e pre-clinici dell'azienda.
Compass Therapeutics (CMPX) ha nombrado a Barry Shin como Director Financiero a partir del 9 de diciembre de 2024. Shin aporta más de 20 años de experiencia en liderazgo biofarmacéutico, incluyendo finanzas, operaciones, banca de inversión y roles de asesoría corporativa. Recientemente, se desempeñó como EVP, COO y CFO en Trevena, Inc.
El nombramiento llega en un momento importante para Compass, con varios catalizadores clave esperados en 2025, incluyendo la lectura de datos de primera línea para CTX-009 en el primer trimestre. El CEO Thomas Schuetz destacó la experiencia de Shin en planificación financiera, mercados de capitales y fusiones y adquisiciones como activos valiosos para avanzar en CTX-009 y el portafolio de activos clínicos y preclínicos de la empresa.
Compass Therapeutics (CMPX)는 Barry Shin을 2024년 12월 9일부터 최고 재무 책임자로 임명했습니다. Shin은 재무, 운영, 투자은행 업무 및 기업 자문 역할을 포함하여 바이오 제약 분야에서 20년 이상의 경험을 가지고 있습니다. 그는 최근 Trevena, Inc.에서 EVP, COO 및 CFO로 근무했습니다.
이번 임명은 Compass에게 중요한 시기에 이루어졌으며, 2025년에는 CTX-009의 주요 데이터 공개를 포함하여 여러 주요 촉매제가 기대되고 있습니다. CEO Thomas Schuetz는 Shin의 재무 계획, 자본 시장 및 M&A에 대한 전문성이 CTX-009와 회사의 임상 및 사전 임상 자산 포트폴리오를 발전시키는 데 소중한 자산이라고 강조했습니다.
Compass Therapeutics (CMPX) a nommé Barry Shin au poste de directeur financier à compter du 9 décembre 2024. Shin a plus de 20 ans d'expérience dans le leadership biopharmaceutique, y compris dans les domaines des finances, des opérations, de la banque d'investissement et du conseil d'entreprise. Récemment, il a occupé le poste d'EVP, COO et CFO chez Trevena, Inc.
Cette nomination intervient à un moment important pour Compass, avec plusieurs catalyseurs clés attendus en 2025, y compris la publication des données principales pour CTX-009 au premier trimestre. Le PDG Thomas Schuetz a souligné que l'expertise de Shin en planification financière, marchés de capitaux et fusions et acquisitions constitue des atouts précieux pour faire avancer CTX-009 et le portefeuille d'actifs cliniques et précliniques de l'entreprise.
Compass Therapeutics (CMPX) hat Barry Shin zum Chief Financial Officer ernannt, der am 9. Dezember 2024 in Kraft tritt. Shin bringt über 20 Jahre Erfahrung in der biopharmazeutischen Führung mit, einschließlich Finanzen, Betrieb, Investmentbanking und Unternehmensberatung. Zuletzt war er als EVP, COO und CFO bei Trevena, Inc. tätig.
Die Ernennung erfolgt zu einem wichtigen Zeitpunkt für Compass, da 2025 mehrere wesentliche Katalysatoren erwartet werden, einschließlich der Veröffentlichung der Hauptdaten für CTX-009 im ersten Quartal. CEO Thomas Schuetz hob Shins Fachkenntnisse in der Finanzplanung, den Kapitalmärkten und Fusionen und Übernahmen als wertvolle Vermögenswerte für die Weiterentwicklung von CTX-009 und dem Portfolio klinischer und präklinischer Vermögenswerte des Unternehmens hervor.
- Strategic timing of CFO appointment ahead of important Q1 2025 clinical data readout
- New CFO brings extensive industry experience in finance, operations, and M&A
- Company has multiple catalysts planned for 2025
- None.
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.
“We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company,” said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. “We have several key catalysts in 2025, including our topline data readout for CTX-009 in the first quarter, and Barry’s deep expertise in financial and strategic planning, capital markets, and M&A will be invaluable as we advance CTX-009 and our broader portfolio of clinical and pre-clinical assets. We are confident Barry will complement our team well and help us deliver value to our shareholders over the coming years.”
“I am excited to join Compass at this critical juncture for the company,” said Mr. Shin. “The data generated by CTX-009 and throughout the broader pipeline is incredibly encouraging and I am thrilled to be a part of the team working to bring important new therapeutic options to patients in need. I look forward to leveraging my financial experience and expertise to help guide the strategy and operations at Compass as it continues to grow and evolve.”
Mr. Shin joins Compass with over two decades of experience in the biopharmaceutical sector as a public company executive, an investment banker, and a corporate attorney. Most recently, he served as Executive Vice President, Chief Operating Officer & Chief Financial Officer at Trevena, Inc., a company that developed and commercialized novel medicines for patients with central nervous system conditions. Previously, Mr. Shin was a Managing Director in the Healthcare Investment Banking Groups at both Mizuho Securities and Guggenheim Securities. He also served in positions of increasing responsibility within the Healthcare Investment Banking Group of Piper Sandler after beginning his career advising healthcare and technology companies in financing and M&A transactions as a corporate attorney. Mr. Shin received a B.Sc. and joint JD/MBA from the University of Toronto.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099
FAQ
When did Barry Shin join Compass Therapeutics (CMPX) as CFO?
What is the next major milestone for Compass Therapeutics (CMPX)?
What was Barry Shin's previous role before joining Compass Therapeutics (CMPX)?
